UPDATE 2-Dendreon files in U.S. for prostate cancer vaccine - News

Runway Angels
The superbowl of fashion shows, models walk down the runway at the 2009 Victoria's Secret Show.
Smartphone Guide
Here's a need-to-know guide to nine devices, based on features, price, network and platform.
Wines for the Holidays
Not quite sure what wine to pair with Turkey or Creme Brulee? Our experts do.

FEATURED QUIZZES

A Healthier & Wealthier You
Take the following quiz and find out how much you know about the impact of obesity on the health of the U.S. economy.
The Billionaire BFF's
Philanthropists. Bridge partners. Hockey players. Which responses are based on facts from Buffett's and Gates' real lives?
The Many Myths of Coca-Cola
Can you tell which statements are true, and which ones are just rumors?

SPECIAL REPORTS

Winterizing Your Portfolio
If 2009 was the winter of our discontent, will 2010 be a winter wonderland for investors? A lot depends on the recovery—or lack thereof.
Investor's Guide to Real Estate
Some even say the long-awaited recovery is here. Regardless, buyers and sellers alike can profit from our guide.
Alternative Investing
Stocks and bonds? Sure. But it's a big world out there for investors.

CNBC ON DIGG

UPDATE 2-Dendreon files in U.S. for prostate cancer vaccine

By: AFX | 02 Nov 2009 | 10:02 AM ET

Text Size

NEW YORK, Nov 2 (Reuters) - Dendreon Corp has completed its U.S. regulatory submission for its closely watched experimental prostate cancer vaccine, the company said on Monday, sending its shares up 5 percent. Dendreon previously said it expected to seek U.S. approval for Provenge in November, and expected regulators to respond by mid-2010. "The submission came a little earlier than had been expected, which was in mid-November, so that is a positive," said Canaccord Adams analyst George Farmer, who estimated the product's sales potential at greater than $4 billion annually by 2020. If approved, Provenge would be the first "therapeutic" cancer vaccine.

While conventional vaccines prevent disease, Provenge treats the condition. "With the (application) submission complete, we have taken an important step towards reaching our goal of bringing a new therapy to men with advanced prostate cancer," Dendreon Chief Executive Mitchell Gold said in a statement. Dendreon in September said it will be able to make enough Provenge to generate potential sales of $60 million to $125 million in the second half of next year. The company said it will steadily ramp up production until full capacity is achieved by late 2011 at plants in New Jersey, Atlanta and Los Angeles, together able to support potential annual sales of $1.2 billion to $2.5 billion. Prostate cancer is diagnosed in one of every six American men and is the second-leading cause of cancer death among men. Dendreon shares, which have soared 10-fold since March, were up 5 percent at $26.55 in morning trading on Nasdaq. (Reporting by Lewis Krauskopf in New York and Susan Kelly in Chicago, editing by Gerald E. McCormick, Dave Zimmerman) Keywords: DENDREON/ (lewis.krauskopf@thomsonreuters.com; 646-223-6082;Reuters Messaging:Lewis.Krauskopf.reuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved.

The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.

Tools: